NCT02428270

A Study of GSK2256098 and Trametinib in Advanced Pancreatic Cancer

Molecular Basket Trial In Multiple Malignancies With Common Target Pathway Aberrancies: A Phase II Trial of GSK2256098 and Trametinib in Patients With Advanced Pancreatic Cancer

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 16 (actual)
• Sponsor: University Health Network, Toronto · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a phase 2 study (the second phase in testing a new drug or combination to see how effect the drug or combination is) of investigational drugs GSK2256098 and Trametinib. The purpose of the study is to evaluate the antitumor activity of GSK2256098 and Trametinib in patients with advanced pancreatic cancer.

Detailed description

Trametinib is a drug that works by binding to and blocking certain proteins called mitogen-activated protein kinase kinase (MEK) 1 and MEK2 from working. MEK1 and MEK2 are important proteins that contribute to the growth of cancer cells. GSK2256098 is a drug that blocks a protein called focal adhesion kinase-1 (FAK) which is an important protein that contribute to the growth of cancer cells.

Conditions

• Pancreatic Cancer
• Adenocarcinoma

Interventions

Type	Name	Description
DRUG	GSK2256098	Small molecule inhibitor of focal adhesion kinase (FAK)
DRUG	Trametinib	Allosteric inhibitor of mitogen-activated extracellular signal-regulated kinase (MEK)1 and MEK2 activation and kinase activity.

Timeline

• Start date: 2016-04-01
• Primary completion: 2017-06-01
• Completion: 2022-10-27
• First posted: 2015-04-28
• Last updated: 2022-11-01

Locations

4 sites across 1 country: Canada